Skip to main content
Fig. 4 | Journal of Hematology & Oncology

Fig. 4

From: A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma

Fig. 4

a Saturation binding curve of 111In-DTPA-2F8 on RPMI 8226 cells. The maximal effective concentration (EC50) was calculated by subtracting non-specific-bound activity (assessed by adding an excess of unlabelled sdAb) from total bound activity and plotted in function of 111In-sdAb concentrations. Data are expressed as mean ± SD. b Ex vivo biodistribution of 111In-DTPA- 2F8 or R3B23 sdAbs. NOD scid gamma mice (n = 3) bearing RPMI 8226 tumour (105 cells injected subcutaneously in the left side) were injected at -1 h with 4.5 ± 0.2 MBq of radiolabelled sdAb and euthanised for organ harvesting. Data displayed on the bar graph are expressed as % IA/g and detailed in Additional file 1: Table 4. c Cell-internalisation assays using sdAb #2F8. (i) Plot representing the internalised fraction of 111In-radiolabelled sdAb #2F8 over time, (ii) membrane-bound fraction of APC-anti-Histag-2F8 over time, assessed via flow cytometry. d In vivo biodistribution of 111In-labelled sdAb #2F8 (18.8 ± 0.1 MBq) + 150 mg/kg gelofusin for a selection of organs and tissues up to 48 h p.i. e Biodistribution of 111In-labelled sdAb #2F8 and the non-targeting sdAb after 1 and 48 h post-tracer administration (18.8 ± 0.1 MBq). Both are co-injected with 150 mg/kg gelofusin. Data are presented as mean ± SD (n = 3) and further detailed in Additional file 1: Tables 5 and 6. Images illustrating these biodistributions are included in Additional file 1: Fig. 2

Back to article page